Evolus, Inc.
Evolus, Inc. (EOLS) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · EOLS · as of Sep 30, 2025
Ownership Breakdown
167
Institutional Holders
▼ 15 vs Q2
$335.55M
Total Inst. Value
▼ $203.23M vs Q2
65.85M
Shares Outstanding
freeFloat 75.99%
54.59M
13F Shares Held
▼ 3.92M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
EOLS largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
NANTAHALA CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 5.73M | 8.87% | 8.87% | $35.16B | Nov 14, 2025 | ▲ 1.53M |
TANG CAPITAL MANAGEMENT LLC pharmaceutical preparations | 5.49M | 8.50% | 8.50% | $33.70B | Nov 14, 2025 | ▲ 490.9K |
BLACKROCK, INC. pharmaceutical preparations | 4.48M | 6.94% | 6.94% | $27.49B | Nov 12, 2025 | ▲ 292.6K |
CALIGAN PARTNERS LP pharmaceutical preparations | 4.14M | 6.41% | 6.41% | $25.41B | Nov 14, 2025 | ▲ 797.0K |
VANGUARD GROUP INC pharmaceutical preparations | 3.43M | 5.31% | 5.31% | $21.05B | Nov 7, 2025 | ▲ 110.7K |
FRAZIER LIFE SCIENCES MANAGEMENT, L.P. pharmaceutical preparations | 2.63M | 4.08% | 4.08% | $16.15B | Nov 14, 2025 | ▲ 195.1K |
MILLENNIUM MANAGEMENT LLC pharmaceutical preparations | 1.86M | 2.88% | 2.88% | $11.41B | Nov 14, 2025 | ▲ 375.6K |
STONEPINE CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 1.54M | 2.38% | 2.38% | $9.43B | Nov 13, 2025 | ▲ 619.9K |
STATE STREET CORP pharmaceutical preparations | 1.52M | 2.35% | 2.35% | $9.30B | Nov 14, 2025 | ▲ 108.6K |
EVERSEPT PARTNERS, LP pharmaceutical preparations | 1.48M | 2.29% | 2.29% | $9.06B | Nov 14, 2025 | ▲ 304.8K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
31
Increased
+7.87M shares5
New Positions
first time holders11
Decreased
−4.42M shares0
Sold Out
fully exitedNet shares change (top 50)
+3.45M
+7.87M / −4.42M
Net new holders
+25
5 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
EOLS insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
16
Buy transactions
6
Sell transactions
2.67
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Avelar Rui See Remarks | Mar 20, 2026 | Sale | 3,119 | $4.75 | $14.8K | 427.4K | Form 4 ↗ |
MOATAZEDI DAVID See Remarks | Mar 20, 2026 | Sale | 13,669 | $4.75 | $64.9K | 604.7K | Form 4 ↗ |
MOATAZEDI DAVID See Remarks | Mar 17, 2026 | Sale | 116,720 | $4.89 | $570.6K | 618.4K | Form 4 ↗ |
Avelar Rui See Remarks | Mar 17, 2026 | Sale | 29,996 | $4.89 | $146.6K | 430.5K | Form 4 ↗ |
Parschauer Karah Herdman director | Feb 17, 2026 | Award | 45,559 | — | — | 77.7K | Form 4 ↗ |
Stewart Brady director | Feb 17, 2026 | Award | 45,559 | — | — | 134.2K | Form 4 ↗ |
Mitchell Tatjana Chief Financial Officer | Feb 17, 2026 | Award | 121,489 | — | — | 226.1K | Form 4 ↗ |
Mitchell Tatjana Chief Financial Officer | Feb 17, 2026 | Award | 177,471 | $4.39 | $779.1K | 177.5K | Form 4 ↗ |
Mitchell Tatjana Chief Financial Officer | Feb 17, 2026 | Award | 121,489 | — | — | 121.5K | Form 4 ↗ |
White Albert G III director | Feb 17, 2026 | Award | 45,559 | — | — | 95.9K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Evolus, Inc. (EOLS) is primarily owned by institutional investors, who hold approximately 82.9% of total shares outstanding. Company insiders own approximately 24.01%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of Evolus, Inc. is NANTAHALA CAPITAL MANAGEMENT, LLC, holding approximately 5.73 million shares — equal to 8.87% of outstanding shares — as of September 30, 2025.
A total of 167 institutional investors currently hold EOLS stock, with a combined institutional value of approximately $335,547,496 as of the most recent 13F filing period.
Frequently asked questions
EOLS ownershipEvolus, Inc. (EOLS) is primarily owned by institutional investors, who hold approximately 82.9% of shares. The largest shareholder is NANTAHALA CAPITAL MANAGEMENT, LLC with a 8.87% stake. Company insiders hold 24.01%. Data sourced from SEC Form 13F as of September 30, 2025.